What’s Next? Five Things To Look Out For In December
Key Trial Kicks Off For Viatris; US Treanda Generics Set To Debut
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
You may also be interested in...
Alvotech Reiterates Meeting US Humira Biosimilar Launch Date
Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.
As US Court Chops Another Symbicort Patent, Will Viatris Make Its Move?
Viatris has persuaded a US district court that a further patent shielding AstraZeneca’s Symbicort pressurized metered dose inhaler is invalid. The ANDA sponsor, holding the only US FDA approval for a generic version of the blockbuster, has the potential to launch – although a further trial is planned in December.
MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”